Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
Public ClinicalTrials.gov record NCT02343406. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
INTELLANCE-2: ABT-414 Alone or ABT-414 Plus Temozolomide Versus Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group
Study identification
- NCT ID
- NCT02343406
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 266 participants
Conditions and interventions
Conditions
Interventions
- Depatuxizumab mafodotin Drug
- Lomustine Drug
- Temozolomide Drug
Drug
Eligibility (public fields only)
- Age range
- Up to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 16, 2015
- Primary completion
- Jun 23, 2019
- Completion
- Jun 23, 2019
- Last update posted
- May 21, 2020
2015 – 2019
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Lucile Packard Children's Hosp /ID# 153678 | Palo Alto | California | 34304 | — |
| Children's Hospital Colorado /ID# 153677 | Aurora | Colorado | 80045 | — |
| Univ of Colorado Cancer Center /ID# 134882 | Aurora | Colorado | 80045 | — |
| Sarah Cannon Research Institute at HealthONE - Denver /ID# 141798 | Denver | Colorado | 80218 | — |
| Rush University Medical Center /ID# 137542 | Chicago | Illinois | 60612 | — |
| Dana-Farber Cancer Institute /ID# 154210 | Boston | Massachusetts | 02215 | — |
| Long Island Brain Tumor Center /ID# 134496 | Lake Success | New York | 11042 | — |
| Weill Cornell Medicine /ID# 152656 | New York | New York | 10032-3725 | — |
| Cleveland Clinic Main Campus /ID# 137540 | Cleveland | Ohio | 44195 | — |
| University of Pittsburgh MC /ID# 134491 | Pittsburgh | Pennsylvania | 15260 | — |
| Tennessee Oncology, PLLC /ID# 134492 | Nashville | Tennessee | 37203 | — |
| UT Southwestern Medical Center /ID# 136718 | Dallas | Texas | 75390-7208 | — |
| Swedish Medical Center /ID# 136719 | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 89 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02343406, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 21, 2020 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02343406 live on ClinicalTrials.gov.